Posted: October 18, 2021 @ 2:12 am EDT|Update: 27 minutes ago
UPPSALA, Sweden, October 18, 2021 / PRNewswire / – Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announced the publication of a manuscript titled “A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA â¢) for Adjunctive Treatment of Opioid Use Disorders: A Developmental Study, âin the Journal of Medical Internet Research (JMIR) Mental Health. The paper describes the development and characteristics of the new digital therapy of company, MODIA â¢. (Link to article: https://mental.jmir.org/2021/10/e31173).
MODIA â¢ was developed by Orexo in collaboration with GAIA SA, and, in July, Orexo was pleased to announce the recruitment of the first participant in a clinical evaluation of MODIA â¢ for the treatment of opioid use disorder (OUD) as part of a clinician-supervised drug-assisted treatment (MAT). Over the next year, MODIA â¢ will be evaluated against the current MAT approach as well as its ability to provide lasting positive results for patients with OUD.
“For over a decade, our primary focus has been on improving the lives of patients suffering from opioid dependence, an experience that has provided us with important and unique information that has been instrumental in the development of MODIA â¢” , noted Mike sumner, chief medical officer, Orexo. âWe know that the ability to combine medication with psychosocial support improves the lives of people with opioid addiction. This article presents our innovative new tool designed to advance this treatment and make it more accessible, regardless of weather or geographic location. . “
Patients with OUD face a myriad of barriers to receiving treatment, including geographic location, a shortage of skilled health providers, and heavy stigma, all of which hinder access to adequate counseling. and the psychosocial support needed for long-term recovery. MODIA â¢ is a digital therapy based on Cognitive Behavioral Therapy (CBT) which has been developed to provide complementary psychological support. MODIA â¢ uses an artificial intelligence approach providing personalized content, messages and tone to meet the patient’s unique needs and circumstances. The patient only needs basic computer skills and internet access.
Nikolaj SÃ¸rensen, President and CEO of Orexo AB, said: âI am delighted that the famous JMIR has published this report to inform the scientific community about the development and functionality of MODIA â¢. Digital therapies have the potential to dramatically improve the efficiency and quality of treatment for several pathological spaces, especially mental health. Obtaining strong clinical evidence is our primary goal and requires us to apply the same scientific rigor to our digital therapies as to our pharmaceuticals. “
MODIA â¢ was developed in close collaboration with OUD specialists and OUD patients at different stages of recovery. The document presents some of the program content, techniques and innovative features of MODIA â¢. It includes some of the attributes and features specifically developed for the OUD patient as an adjunct to the MAT therapeutic approach and to support positive patient outcomes. The document is written by Bjorn meyer, Ph.D. (GAIA SA), Geri-Lynn Utter, Psy.D. (Orexo US)., And Catherine hillman, Psy.D.
For more information, please contact:
Orexo AB (publisher)
About the MODIA â¢ pivotal study
The pivotal, randomized, open-label, parallel-group study will assess whether the use of MODIA â¢ in combination with maintenance therapy with buprenorphine / sublingual naloxone is superior to buprenorphine / sublingual naloxone alone in reducing opioid use. . The study is designed to recruit approximately 400 participants aged 18 to 65 across the United States who voluntarily seek treatment for documented moderate to severe TOU. Participants will be assessed over a 24 week period, including a screening period during which they will be stabilized on buprenorphine / naloxone, with a primary endpoint defined as subject having â¥ 80% of drug tests in urine negative for opioids and negative self-reports for opioids. illicit use of opioids during the study period. For more information on the study, please visit www.clinicaltrials.gov.
Orexo develops improved pharmaceuticals and digital therapies that address unmet needs in the growing space of substance use disorders and mental illness. The products are marketed by Orexo in the United States or through partners around the world. The primary market today is the US buprenorphine / naloxone market, where Orexo markets its flagship product, ZUBSOLVÂ®, for the treatment of opioid use disorders. Orexo’s total turnover in 2020 amounts to 664 million Swedish kronor and the number of employees was 138. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADR on OTCQX (ORXOY) in the United States. The company is headquartered in Uppsala, Sweden, where research and development activities are carried out.
For more information on Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
The information has been submitted for publication to 8:00 am CET, to October 18, 2021.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Show original content:
The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.